Results 41 to 50 of about 389,233 (339)

Immune Checkpoint Molecules in Reproductive Immunology

open access: yesFrontiers in Immunology, 2019
Immune checkpoint molecules, like CTLA-4, TIM-3, PD-1, are negative regulators of immune responses to avoid immune injury. Checkpoint regulators are thought to actively participate in the immune defense of infections, prevention of autoimmunity ...
Eva Miko   +8 more
doaj   +1 more source

SnapShot: Immune Checkpoint Inhibitors

open access: yesCancer Cell, 2017
Immunotherapy has changed the landscape of cancer treatment. Checkpoint blockade therapies unleash breaks in the immune system and induce long-lasting responses. However, a significant number of patients do not respond (innate resistance), and a subset progress after responding (acquired resistance).
Abril-Rodriguez, Gabriel, Ribas, Antoni
openaire   +4 more sources

Nifuroxazide suppresses PD-L1 expression and enhances the efficacy of radiotherapy in hepatocellular carcinoma

open access: yeseLife
Radiation therapy is a primary treatment for hepatocellular carcinoma (HCC), but its effectiveness can be diminished by various factors. The over-expression of PD-L1 has been identified as a critical reason for radiotherapy resistance.
Tiesuo Zhao   +19 more
doaj   +1 more source

Reprogramming the tumor microenvironment to overcome immunotherapy resistance in pancreatic cancer

open access: yesFrontiers in Immunology
BackgroundPancreatic ductal adenocarcinoma (PDAC) exhibits profound resistance to immunotherapy due to its highly immunosuppressive tumor microenvironment (TME).ObjectiveThis review aims to elucidate the key mechanisms of TME-mediated immune evasion in ...
Xianfeng Hui   +11 more
doaj   +1 more source

Key questions about the checkpoint blockade-are microRNAs an answer?

open access: yesCancer Biology & Medicine, 2018
The introduction of immune-checkpoint blockade in the cancer therapy led to a paradigm change of the management of late stage cancers. There are already multiple FDA approved checkpoint inhibitors and many other agents are undergoing phase 2 and early ...
Mihnea Dragomir   +3 more
doaj   +1 more source

Review of precision cancer medicine: Evolution of the treatment paradigm. [PDF]

open access: yes, 2020
In recent years, biotechnological breakthroughs have led to identification of complex and unique biologic features associated with carcinogenesis. Tumor and cell-free DNA profiling, immune markers, and proteomic and RNA analyses are used to identify ...
Fountzilas, Elena   +3 more
core   +1 more source

Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response. [PDF]

open access: yes, 2019
Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide and confers a poor prognosis. Beyond standard systemic therapy with multikinase inhibitors, recent studies demonstrate the potential for robust and durable responses ...
Fong, Lawrence   +2 more
core   +2 more sources

Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas [PDF]

open access: yes, 2018
This integrated, multiplatform PanCancer Atlas study co-mapped and identified distinguishing molecular features of squamous cell carcinomas (SCCs) from five sites associated with ...
Abdel-Rahman, Mohamed H.   +784 more
core   +2 more sources

Prolonged Corrected QT Interval as an Early Electrocardiographic Marker of Cyclophosphamide‐Induced Cardiotoxicity in Pediatric Hematology and Oncology Patients

open access: yesPediatric Blood &Cancer, EarlyView.
ABSTRACT Background Cyclophosphamide (CY) is associated with potentially fatal cardiotoxicity, yet no electrocardiographic indices have been established for early detection of CY‐induced cardiomyopathy. This study aimed to determine whether corrected QT interval (QTc) prolongation can predict early onset of CY‐related cardiac dysfunction in pediatric ...
Junpei Kawamura   +5 more
wiley   +1 more source

Pneumonitis and multiple pneumonial infections under combined immune‐checkpoint inhibition

open access: yesJEADV Clinical Practice, 2023
The introduction of immune checkpoint inhibitors and targeted therapies has revolutionized melanoma treatment. The downside are immune‐mediated adverse events which are frequent and require close patient management.
Kristine E. Mayer   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy